Zhejiang Shengda Pharm (603079) - Total Liabilities

Latest as of September 2025: CN¥542.15 Million CNY ≈ $79.33 Million USD

Based on the latest financial reports, Zhejiang Shengda Pharm (603079) has total liabilities worth CN¥542.15 Million CNY (≈ $79.33 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 603079 operating cash flow to assess how effectively this company generates cash.

Zhejiang Shengda Pharm - Total Liabilities Trend (2012–2024)

This chart illustrates how Zhejiang Shengda Pharm's total liabilities have evolved over time, based on quarterly financial data. Check 603079 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Zhejiang Shengda Pharm Competitors by Total Liabilities

The table below lists competitors of Zhejiang Shengda Pharm ranked by their total liabilities.

Company Country Total Liabilities
Symtek Automation Asia Co Ltd
TW:6438
Taiwan NT$4.16 Billion
WideOpenWest Inc
NYSE:WOW
USA $1.36 Billion
Investors Title Company
NASDAQ:ITIC
USA $94.84 Million
Kerry TJ Logistics Co Ltd
TW:2608
Taiwan NT$11.92 Billion
Sampoerna Agro Tbk
JK:SGRO
Indonesia Rp4.20 Trillion
HiVi Acoustics Technology Co Ltd
SHE:002888
China CN¥66.63 Million
San Fu Chemical Co Ltd
TW:4755
Taiwan NT$3.19 Billion
Inzone Group Co Ltd
SHG:600858
China CN¥8.77 Billion

Liability Composition Analysis (2012–2024)

This chart breaks down Zhejiang Shengda Pharm's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Zhejiang Shengda Pharm (603079) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 4.41 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.34 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.25 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Zhejiang Shengda Pharm's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Zhejiang Shengda Pharm (2012–2024)

The table below shows the annual total liabilities of Zhejiang Shengda Pharm from 2012 to 2024.

Year Total Liabilities Change
2024-12-31 CN¥501.34 Million
≈ $73.36 Million
+11.61%
2023-12-31 CN¥449.20 Million
≈ $65.73 Million
+44.08%
2022-12-31 CN¥311.76 Million
≈ $45.62 Million
-27.13%
2021-12-31 CN¥427.84 Million
≈ $62.61 Million
+13.85%
2020-12-31 CN¥375.80 Million
≈ $54.99 Million
-39.47%
2019-12-31 CN¥620.88 Million
≈ $90.85 Million
+46.33%
2018-12-31 CN¥424.29 Million
≈ $62.09 Million
+95.28%
2017-12-31 CN¥217.27 Million
≈ $31.79 Million
-27.90%
2016-12-31 CN¥301.35 Million
≈ $44.10 Million
+62.85%
2015-12-31 CN¥185.05 Million
≈ $27.08 Million
-17.17%
2014-12-31 CN¥223.40 Million
≈ $32.69 Million
-0.27%
2013-12-31 CN¥224.00 Million
≈ $32.78 Million
-30.31%
2012-12-31 CN¥321.43 Million
≈ $47.04 Million
--

About Zhejiang Shengda Pharm

SHG:603079 China Drug Manufacturers - Specialty & Generic
Market Cap
$441.19 Million
CN¥3.02 Billion CNY
Market Cap Rank
#13256 Global
#4189 in China
Share Price
CN¥15.95
Change (1 day)
+0.31%
52-Week Range
CN¥15.36 - CN¥21.99
All Time High
CN¥53.01
About

Zhejiang Shengda Bio-Pharm Co., Ltd. develops, produces, and sells food and feed additives for pharmaceutical, nutritional, food, and animal feed industry. It offers vitamins, such as biotin and folic acid; biological preservatives, including nisin, polylysine, and natamycin; and intermediate APIs. The company was incorporated in 1999 and is headquartered in Tiantai, China.